Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
Home » Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)

GH AMEA on Social Media Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
The Korea Herald

Congratulations to #Yuhan for its recent approval of Leclaza (Lazertinib) for lung cancer treatment by Korea’s Ministry of Food and Drug Safety. https://lnkd.in/grU_-jC

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us
Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib) - Guardant Health AMEA

Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
Home » Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)

GH AMEA on Social Media Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
Congratulations to Yuhan for its recent approval of Leclaza (Lazertinib)
The Korea Herald

Congratulations to #Yuhan for its recent approval of Leclaza (Lazertinib) for lung cancer treatment by Korea’s Ministry of Food and Drug Safety. https://lnkd.in/grU_-jC

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us